We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER Finds Janssen’s Treatment-Resistant Depression Spray Too Pricey
ICER Finds Janssen’s Treatment-Resistant Depression Spray Too Pricey
Janssen’s Spravato (esketamine) spray—approved by the FDA in March for treatment-resistant depression —isn’t cost-effective at its listed price, a nonprofit drug price watchdog says.